Kodiak Sciences Inc. (KOD) shareholders
Close on Nov 17, 2026Market cap $6.08BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Baker Bros. Advisors LP Joint filing with Baker Bros. Advisors (GP) LLC (35.00%), Julian C. Baker (35.00%) and 1 more | 22,049,297 | 35.00% | 13D (active) amendment | Sep 28, 2026 |
| Felix J. Baker Joint filing with Baker Bros. Advisors LP (32.80%), Baker Bros. Advisors (GP) LLC (32.80%) and 1 more | 20,067,542 | 32.80% | 13D (active) amendment | Dec 18, 2025 |
| D. Victor Perlroth, M.D. | 6,504,427 | 9.90% | 13G (passive) amendment | Dec 31, 2025 |
| Alex Silverstein Joint filing with Sirenia Capital Management LP (5.70%) | 3,495,000 | 5.70% | 13G (passive) | Mar 31, 2026 |
| BlackRock, Inc. | 3,273,386 | 5.30% | 13G (passive) | Mar 31, 2026 |
| T. Rowe Price Associates, Inc. | 3,248,611 | 5.20% | 13G (passive) | Jun 30, 2026 |
| Point72 Capital Advisors, Inc. Joint filing with Point72 Asset Management, L.P. (5.50%), Steven A. Cohen (5.50%) | 2,908,836 | 5.50% | 13G (passive) | Aug 15, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of KOD | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 19,919,186 | 31.69% | $776.05M | – | 3.89% |
| BlackRock, Inc. | 4,135,355 | 6.58% | $161.11M | +200,053 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 3,248,611 | 5.17% | $126.57M | +1,209,261 | 0.01% |
| State Street Corp | 2,419,417 | 3.85% | $94.26M | +168,497 | 0.00% |
| Goldman Sachs Group Inc | 2,316,014 | 3.69% | $90.23M | +627,011 | 0.01% |
| Vanguard Capital Management LLC | 1,804,632 | 2.87% | $70.31M | +87,556 | 0.00% |
| Braidwell LP | 1,787,318 | 2.84% | $69.63M | −31,347 | 2.58% |
| Jupiter Topco LLC | 1,526,006 | 2.43% | $59.51M | New | 0.02% |
| Rtw Investments, LP | 1,487,934 | 2.37% | $57.97M | – | 0.49% |
| Boxer Capital Management, LLC | 1,477,600 | 2.35% | $57.57M | +116,600 | 4.34% |
| T. Rowe Price Investment Management, Inc. | 1,477,033 | 2.35% | $57.55M | +640,089 | 0.04% |
| TCG Crossover Management, LLC | 1,445,538 | 2.30% | $56.32M | – | 1.35% |
| ICONIQ Capital, LLC | 1,266,563 | 2.02% | $49.35M | – | 1.42% |
| Geode Capital Management, LLC | 1,062,955 | 1.69% | $41.42M | +62,544 | 0.00% |
| Ikarian Capital, LLC | 1,059,730 | 1.69% | $41.29M | −206,065 | 4.45% |
| Artisan Partners Limited Partnership | 968,037 | 1.54% | $37.71M | +277,715 | 0.06% |
| Wellington Management Group Llp | 793,613 | 1.26% | $30.92M | +357,284 | 0.01% |
| Board of Trustees of The Leland Stanford Junior University | 691,767 | 1.10% | $26.95M | – | 5.06% |
| Silverarc Capital Management, LLC | 546,256 | 0.87% | $21.28M | −445,674 | 2.21% |
| Vanguard Portfolio Management LLC | 532,819 | 0.85% | $20.76M | +167,768 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 200 | 60M | 96.2% | 39 / 82 | 55 / 23 | 8M | 4M |
| Q1 2026 | 188 | 58M | 92.2% | 53 / 64 | 52 / 20 | 9M | 6M |
| Q4 2025 | 158 | 58M | 91.6% | 51 / 49 | 41 / 13 | 18M | 4M |
| Q3 2025 | 121 | 45M | 70.8% | 30 / 33 | 34 / 9 | 7M | 5M |
| Q2 2025 | 100 | 42M | 66.6% | 9 / 33 | 34 / 16 | 2M | 3M |
| Q1 2025 | 107 | 43M | 68.3% | 21 / 40 | 30 / 19 | 4M | 4M |
| Q4 2024 | 107 | 42M | 67.0% | 23 / 32 | 29 / 14 | 6M | 4M |
| Q3 2024 | 98 | 39M | 62.8% | 12 / 26 | 29 / 18 | 5M | 2M |
| Q2 2024 | 106 | 40M | 63.8% | 22 / 31 | 27 / 28 | 1M | 6M |
| Q1 2024 | 113 | 45M | 71.9% | 31 / 26 | 38 / 14 | 8M | 4M |
| Q4 2023 | 96 | 41M | 65.7% | 17 / 41 | 18 / 22 | 3M | 4M |
| Q3 2023 | 101 | 43M | 67.6% | 14 / 36 | 30 / 41 | 6M | 6M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
210 funds held KOD in Q2 2026, 49% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of KOD | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,495,246 | 2.38% | $58.25M | 0.54% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,288,755 | 2.05% | $50.21M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,022,270 | 1.63% | $39.83M | 0.05% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1,013,711 | 1.61% | $39.49M | 0.33% | Jun 30, 2026 |
| Artisan International Small-Mid Fund | 595,991 | 0.95% | $23.22M | 0.91% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 590,816 | 0.94% | $23.02M | 0.16% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 498,300 | 0.79% | $19.41M | 0.20% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 475,615 | 0.76% | $18.53M | 0.02% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 430,495 | 0.68% | $17.90M | 0.05% | Jul 31, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 426,474 | 0.68% | $16.62M | 0.18% | Jun 30, 2026 |
| iShares Biotechnology ETF | 410,488 | 0.65% | $15.99M | 0.18% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 347,467 | 0.55% | $13.54M | 0.09% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 268,157 | 0.43% | $10.45M | 0.10% | Jun 30, 2026 |
| Vanguard Explorer Fund | 245,680 | 0.39% | $10.22M | 0.05% | Jul 31, 2026 |
| T. Rowe Price Institutional Small-Cap Stock Fund | 229,223 | 0.36% | $8.93M | 0.18% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Victor Perlroth | Chairman and CEO, Director, 10% owner | 3,732,242 | 5.94% | Sep 29, 2026 |
| John A. Borgeson | Chief Financial Officer | 211,930 | 0.34% | Oct 23, 2026 |
| Julian Baker | Director, 10% owner | 19,221,341 | 30.58% | Nov 6, 2026 |
| Felix Baker | Director, 10% owner | 15,455,507 | 24.59% | Nov 6, 2026 |
| Brothers Life Sciences LP Baker | Director, 10% owner | 18,358,772 | 29.21% | Nov 6, 2026 |
| Bros. Advisors (GP) LLC Baker | Director, 10% owner | 18,373,116 | 29.23% | Nov 6, 2026 |
| 667, L.P. | Director, 10% owner | 1,669,727 | 2.66% | Nov 6, 2026 |
| Bros. Advisors Lp Baker | Director, 10% owner | 20,424,859 | 32.50% | Nov 6, 2026 |
| Taiyin Yang | Director | 20,000 | 0.03% | Oct 26, 2026 |
| Richard S. Levy | Director | 250 | 0.00% | Jul 2, 2026 |
| Robert Profusek | Director | 10,000 | 0.02% | Jul 2, 2026 |
| Bassil I. Dahiyat | Director | – | – | Jul 2, 2026 |
| Charles A. Bancroft | Director | 25,948 | 0.04% | Jul 2, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Bros. Advisors Lp Baker Director, 10% owner | Nov 5, 2026 | Buy | +81,729 | $98.51 | $8.05M | 20,424,859 |
| Bros. Advisors Lp Baker Director, 10% owner | Nov 5, 2026 | Buy | +4,703 | $98.51 | $463.29K | 1,683,172 |
| Bros. Advisors Lp Baker Director, 10% owner | Nov 4, 2026 | Buy | +151,916 | $98.51 | $14.97M | 20,343,130 |
| Bros. Advisors Lp Baker Director, 10% owner | Nov 4, 2026 | Buy | +8,742 | $98.51 | $861.17K | 1,678,469 |
| Taiyin Yang Director | Oct 23, 2026 | Option exercise | +20,000 | $2.35 | $47.00K | 20,000 |
| John A. Borgeson Chief Financial Officer | Oct 21, 2026 | Sale(10b5-1 plan) | −100 | $94.91 | $9.49K | 211,930 |
| John A. Borgeson Chief Financial Officer | Oct 21, 2026 | Sale(10b5-1 plan) | −2,000 | $93.71 | $187.42K | 212,030 |
| John A. Borgeson Chief Financial Officer | Oct 21, 2026 | Sale(10b5-1 plan) | −2,000 | $92.66 | $185.32K | 214,030 |
| John A. Borgeson Chief Financial Officer | Oct 21, 2026 | Sale(10b5-1 plan) | −2,985 | $91.76 | $273.90K | 216,030 |
| John A. Borgeson Chief Financial Officer | Oct 21, 2026 | Sale(10b5-1 plan) | −5,101 | $90.98 | $464.09K | 219,015 |
| John A. Borgeson Chief Financial Officer | Oct 21, 2026 | Sale(10b5-1 plan) | −7,623 | $89.74 | $684.09K | 224,116 |
| John A. Borgeson Chief Financial Officer | Oct 21, 2026 | Sale(10b5-1 plan) | −1,677 | $89.20 | $149.59K | 231,739 |
| John A. Borgeson Chief Financial Officer | Oct 21, 2026 | Sale(10b5-1 plan) | −8,514 | $87.67 | $746.42K | 233,416 |
| John A. Borgeson Chief Financial Officer | Oct 21, 2026 | Option exercise | +30,000 | $2.49 | $74.70K | 241,930 |
| 667, L.P. Director, 10% owner | Sep 29, 2026 | Buy | +84 | $85.89 | $7.21K | 1,669,727 |
| 667, L.P. Director, 10% owner | Sep 29, 2026 | Buy | +20,031 | $85.40 | $1.71M | 20,189,798 |
| 667, L.P. Director, 10% owner | Sep 29, 2026 | Buy | +1,195 | $85.40 | $102.05K | 1,669,643 |
| 667, L.P. Director, 10% owner | Sep 29, 2026 | Buy | +10,381 | $84.24 | $874.50K | 20,169,767 |
| 667, L.P. Director, 10% owner | Sep 29, 2026 | Buy | +619 | $84.24 | $52.14K | 1,668,448 |
| 667, L.P. Director, 10% owner | Sep 29, 2026 | Buy | +1,416 | $85.89 | $121.62K | 20,191,214 |
| Julian Baker Director, 10% owner | Sep 28, 2026 | Buy | +28,028 | $81.82 | $2.29M | 19,221,341 |
| Julian Baker Director, 10% owner | Sep 28, 2026 | Buy | +1,672 | $81.82 | $136.80K | 1,611,870 |
| Julian Baker Director, 10% owner | Sep 28, 2026 | Buy | +39 | $81.92 | $3.19K | 1,611,909 |
| Julian Baker Director, 10% owner | Sep 28, 2026 | Buy | +651 | $81.92 | $53.33K | 19,221,992 |
| Julian Baker Director, 10% owner | Sep 28, 2026 | Buy | +101 | $82.68 | $8.35K | 1,612,010 |
| Julian Baker Director, 10% owner | Sep 28, 2026 | Buy | +1,699 | $82.68 | $140.47K | 19,223,691 |
| Julian Baker Director, 10% owner | Sep 28, 2026 | Buy | +1,167 | $83.16 | $97.05K | 1,613,177 |
| Julian Baker Director, 10% owner | Sep 28, 2026 | Buy | +19,554 | $83.16 | $1.63M | 19,243,245 |
| Julian Baker Director, 10% owner | Sep 28, 2026 | Buy | +7,390 | $83.95 | $620.39K | 1,620,567 |
| Julian Baker Director, 10% owner | Sep 28, 2026 | Buy | +123,888 | $83.95 | $10.40M | 19,367,133 |
| Julian Baker Director, 10% owner | Sep 28, 2026 | Buy | +6,553 | $84.85 | $556.02K | 1,627,120 |
| Julian Baker Director, 10% owner | Sep 28, 2026 | Buy | +109,842 | $84.85 | $9.32M | 19,476,975 |
| Julian Baker Director, 10% owner | Sep 28, 2026 | Buy | +2,322 | $85.97 | $199.62K | 1,629,442 |
| Julian Baker Director, 10% owner | Sep 28, 2026 | Buy | +38,932 | $85.97 | $3.35M | 19,515,907 |
| Julian Baker Director, 10% owner | Sep 28, 2026 | Buy | +534 | $79.40 | $42.40K | 1,606,426 |
| Julian Baker Director, 10% owner | Sep 28, 2026 | Buy | +8,956 | $79.40 | $711.11K | 19,130,090 |
| Julian Baker Director, 10% owner | Sep 28, 2026 | Buy | +17 | $79.63 | $1.35K | 1,606,443 |
| Julian Baker Director, 10% owner | Sep 28, 2026 | Buy | +283 | $79.63 | $22.54K | 19,130,373 |
| Julian Baker Director, 10% owner | Sep 28, 2026 | Buy | +884 | $79.71 | $70.46K | 1,607,327 |
| Julian Baker Director, 10% owner | Sep 28, 2026 | Buy | +14,827 | $79.71 | $1.18M | 19,145,200 |
| Julian Baker Director, 10% owner | Sep 28, 2026 | Buy | +404 | $80.23 | $32.41K | 1,607,731 |
| Julian Baker Director, 10% owner | Sep 28, 2026 | Buy | +6,783 | $80.23 | $544.20K | 19,151,983 |
| Julian Baker Director, 10% owner | Sep 28, 2026 | Buy | +61 | $80.52 | $4.91K | 1,607,792 |
| Julian Baker Director, 10% owner | Sep 28, 2026 | Buy | +1,027 | $80.52 | $82.69K | 19,153,010 |
| Julian Baker Director, 10% owner | Sep 28, 2026 | Buy | +17,490 | $81.31 | $1.42M | 19,193,313 |
| Julian Baker Director, 10% owner | Sep 28, 2026 | Buy | +1,044 | $81.31 | $84.89K | 1,610,198 |
| Julian Baker Director, 10% owner | Sep 28, 2026 | Buy | +5,654 | $81.20 | $459.10K | 19,175,823 |
| Julian Baker Director, 10% owner | Sep 28, 2026 | Buy | +338 | $81.20 | $27.45K | 1,609,154 |
| Julian Baker Director, 10% owner | Sep 28, 2026 | Buy | +17,159 | $81.02 | $1.39M | 19,170,169 |
| Julian Baker Director, 10% owner | Sep 28, 2026 | Buy | +1,024 | $81.02 | $82.96K | 1,608,816 |
| Bros. Advisors (GP) LLC Baker Director, 10% owner | Sep 28, 2026 | Buy | +14,344 | $61.21 | $878.00K | 18,373,116 |
| Bros. Advisors (GP) LLC Baker Director, 10% owner | Sep 28, 2026 | Buy | +321 | $67.10 | $21.54K | 1,564,979 |
| Bros. Advisors (GP) LLC Baker Director, 10% owner | Sep 28, 2026 | Buy | +5,382 | $67.10 | $361.13K | 18,435,276 |
| Bros. Advisors (GP) LLC Baker Director, 10% owner | Sep 28, 2026 | Buy | +154 | $68.37 | $10.53K | 1,565,133 |
| Bros. Advisors (GP) LLC Baker Director, 10% owner | Sep 28, 2026 | Buy | +2,585 | $68.37 | $176.74K | 18,437,861 |
| Bros. Advisors (GP) LLC Baker Director, 10% owner | Sep 28, 2026 | Buy | +2,331 | $68.96 | $160.75K | 1,567,464 |
| Bros. Advisors (GP) LLC Baker Director, 10% owner | Sep 28, 2026 | Buy | +39,066 | $68.96 | $2.69M | 18,476,927 |
| Bros. Advisors (GP) LLC Baker Director, 10% owner | Sep 28, 2026 | Buy | +1,056 | $71.48 | $75.48K | 1,568,520 |
| Bros. Advisors (GP) LLC Baker Director, 10% owner | Sep 28, 2026 | Buy | +17,698 | $71.48 | $1.27M | 18,494,625 |
| Bros. Advisors (GP) LLC Baker Director, 10% owner | Sep 28, 2026 | Buy | +16,641 | $72.39 | $1.20M | 1,585,161 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Kodiak Sciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 185,489 shares on Sep 29, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| John A. Borgeson Officer | Oct 21, 2026 | 30,000 | $2.79M | Oct 21, 2026 | Exercise of Stock Options |
| John A. Borgeson Officer | Jun 4, 2026 | 30,000 | $1.02M | Jun 4, 2026 | Exercise of Stock Options |
| John A. Borgeson Officer | Apr 2, 2026 | 30,000 | $1.28M | Apr 2, 2026 | Exercise of Stock Options |
Congress trades
2 trades in Kodiak Sciences reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Christopher L. Jacobs NY27 | Sold | Nov 8, 2022 | $1K–15K | Dec 12, 2022 |
| Christopher L. Jacobs NY27 | Bought | Jul 18, 2022 | $1K–15K | Sep 9, 2022 53 days late |
See a number that looks wrong?